News + Resources
Life Sciences Mergers and Acquisitions: A Vital Bridge Across the “Valley of Death”
Every day, life sciences innovators discover promising new therapies with the potential to transform our approach to treating life-altering or life-threatening diseases. But what lies between these initial discoveries and an FDA-approved treatment reaching patients is the so-called “valley of death” – the considerable scientific, regulatory and financial hurdles that life sciences companies must overcome to bring their biopharmaceutical breakthroughs to market.
M&A Provides Vital Bridge for Life Science Innovation Amid Economic Headwinds, Market Demands
In one of the more challenging investment economies in decades, life science innovators are increasingly forced to face difficult economic headwinds and market demands in their pursuit of breakthrough treatments and cures.
In Case You Missed It: American Enterprise Institute Panelists Weigh in on FTC & DOJ’s Flawed Approach to Merger Enforcement
Following the public comment period on the FTC and DOJ’s proposed merger guidelines, leading antitrust experts and economists expressed significant concerns about the dramatic shift in competition policy that the proposal represents. In a recent panel discussion hosted by AEI, panelists zeroed in on the gaps in the proposed guidelines and the broad impact that they would have on consumers, underscoring the importance of a balanced approach to merger enforcement.
U.S. Chamber of Commerce Survey: Regulators’ Proposed Approach to M&A Ignores Market Reality
A recent survey by the U.S Chamber of Commerce sheds new light on the flaws of the Federal Trade Commission (FTC) and Department of Justice’s proposed approach to review and enforcement of mergers and acquisitions (M&A).
What They Are Saying: Proposed Premerger Review Rules Would Burden Life Sciences Innovators, Impede Vital New Therapies
In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement.
What They Are Saying: Proposed Merger Guidelines Would Stall Innovation, Slowing Treatments and Cures for Patients
In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement.
Politico Op-ed: The Justice Department Controversy You Might Have Missed
In a recent op-ed for Politico, Ankush Khardori, an attorney and former federal prosecutor for the Department of Justice (DOJ), points out the noticeable lack of evidence behind the DOJ and Federal Trade Commissions’ (FTC) proposed merger guidelines.
Life Sciences Leaders, Advocates Launch New Partnership to Promote Benefits of Pro-Innovation Mergers & Acquisitions
More than thirty leading organizations from across the life sciences today launched the Partnership for the U.S. Life Science Ecosystem (PULSE), a coalition to raise awareness of the fundamental role of pro-innovation mergers and acquisitions (M&A) in advancing the next generation of treatments and cures for patients.
Life Sciences Mergers and Acquisitions (M&A): Myths vs. Facts
Mergers and acquisitions (M&A) allow life sciences companies of all sizes to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Decades of pro-innovation policies have helped catalyze this by incentivizing M&A and establishing it as an important tool.
Pro-Innovation Mergers & Acquisitions: Maintaining America’s Leadership in Biopharmaceutical Breakthroughs
Thousands of U.S. life sciences companies race every day to find better treatments and cures for a wide range of conditions and diseases. Within this diverse and dynamic life sciences ecosystem – made up of early-stage companies, large-scale entities, research universities and other researchers across the public and private sectors – mergers and acquisitions (M&A) fuel America’s global leadership in biopharmaceutical breakthroughs.